CD8A and neoplasm: Interestingly, the FXR antagonist UDCA, in combination with anti-PD-1Ab, also shows a stronger anti-tumor effect in a CRC mouse model, accompanied by increased anti-tumor CD8+ T-cell responses, decreased Treg cells among TILs, and enhanced tumor-specific immune memory [169,170].